安全网医疗保健系统中具有药物基因组学可操作性的药物。
Pharmacogenomically actionable medications in a safety net health care system.
作者信息
Carpenter Janet S, Rosenman Marc B, Knisely Mitchell R, Decker Brian S, Levy Kenneth D, Flockhart David A
机构信息
Department of Science of Nursing Care, School of Nursing, Indiana University, Indianapolis, IN, USA.
Department of Pediatrics, Indiana University, Indianapolis, IN, USA.
出版信息
SAGE Open Med. 2016 Jan 7;4:2050312115624333. doi: 10.1177/2050312115624333. eCollection 2016.
OBJECTIVE
Prior to implementing a trial to evaluate the economic costs and clinical outcomes of pharmacogenetic testing in a large safety net health care system, we determined the number of patients taking targeted medications and their clinical care encounter sites.
METHODS
Using 1-year electronic medical record data, we evaluated the number of patients who had started one or more of 30 known pharmacogenomically actionable medications and the number of care encounter sites the patients had visited.
RESULTS
Results showed 7039 unique patients who started one or more of the target medications within a 12-month period with visits to 73 care sites within the system.
CONCLUSION
Findings suggest that the type of large-scale, multi-drug, multi-gene approach to pharmacogenetic testing we are planning is widely relevant, and successful implementation will require wide-scale education of prescribers and other personnel involved in medication dispensing and handling.
目的
在大型安全网医疗保健系统中开展一项评估药物基因组检测的经济成本和临床结果的试验之前，我们确定了服用靶向药物的患者数量及其临床护理就诊地点。
方法
利用1年的电子病历数据，我们评估了开始使用30种已知具有药物基因组学可作用药物中的一种或多种的患者数量，以及患者就诊的护理地点数量。
结果
结果显示，在12个月内，有7039名不同患者开始使用一种或多种靶向药物，并在该系统内的73个护理地点就诊。
结论
研究结果表明，我们计划采用的大规模、多药物、多基因的药物基因组检测方法具有广泛的相关性，成功实施将需要对开处方者和其他参与药物调配和处理的人员进行广泛的教育。
Zotero 插件